Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone510-550-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.82 million
Profitability
Miscellaneous
Employees90
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Zogenix (NASDAQ:ZGNX) Frequently Asked Questions
What is Zogenix's stock symbol?
Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."
How were Zogenix's earnings last quarter?
Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings results on Monday, August, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.06. During the same quarter last year, the firm earned ($0.90) earnings per share. View Zogenix's Earnings History.
When is Zogenix's next earnings date?
What price target have analysts set for ZGNX?
10 equities research analysts have issued 12 month target prices for Zogenix's shares. Their forecasts range from $60.00 to $116.00. On average, they expect Zogenix's share price to reach $72.6667 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price. View Analyst Price Targets for Zogenix.
What is the consensus analysts' recommendation for Zogenix?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.
What are Wall Street analysts saying about Zogenix stock?
Here are some recent quotes from research analysts about Zogenix stock:
- 1. Mizuho analysts commented, "We gave consideration to (70% PoS). DCF: We assumed a 13% discount rate and a terminal value of 4.5x our estimated 2028 FCF of $861 mil. EV/Sales: we apply a 8x multiple to discounted 2025 sales of $352 mil. the U.S. market, we assume 4Q19 launch and peak market share of 75% (among new therapies) in 2028, equivalent to $526mn in peak sales; for EU and Japan, we assume late 2021 and late 2022 launches. For LGS, we project peak market penetration of 14% in 2028 in the U.S and PoS adjusted sales of $463mn." (3/19/2019)
- 2. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (2/23/2019)
Has Zogenix been receiving favorable news coverage?
Media stories about ZGNX stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zogenix earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Zogenix's key competitors?
Some companies that are related to Zogenix include Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR) and GALAPAGOS NV/S (GLPG).
What other stocks do shareholders of Zogenix own?
Who are Zogenix's key executives?
Zogenix's management team includes the folowing people:
- Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
- Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 66)
- Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
- Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
- Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
Who are Zogenix's major shareholders?
Zogenix's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (9.97%), BlackRock Inc. (8.54%), Bank of New York Mellon Corp (5.79%), RA Capital Management LLC (5.68%), venBio Select Advisor LLC (4.71%) and Great Point Partners LLC (2.38%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix.
Which institutional investors are selling Zogenix stock?
ZGNX stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Broadfin Capital LLC, Bank of New York Mellon Corp, Polar Capital LLP, Barclays PLC, Emerald Advisers LLC, Two Sigma Advisers LP and BlackRock Inc.. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix.
Which institutional investors are buying Zogenix stock?
ZGNX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Great Point Partners LLC, Westfield Capital Management Co. LP, venBio Select Advisor LLC, RA Capital Management LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Eversept Partners LP. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer and Life Sciences Maste Perceptive. View Insider Buying and Selling for Zogenix.
How do I buy shares of Zogenix?
Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zogenix's stock price today?
One share of ZGNX stock can currently be purchased for approximately $52.16.
How big of a company is Zogenix?
Zogenix has a market capitalization of $2.20 billion and generates $9.82 million in revenue each year. The company earns $-123,910,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Zogenix employs 90 workers across the globe.
What is Zogenix's official website?
How can I contact Zogenix?
Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]
MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
